Endo, INC Form 4 insider transactions

Mallinckrodt and Endo are urging their respective shareholders to vote in favor of the proposed business combination at the upcoming special meetings on June 13, 2025.

Mallinckrodt and Endo report significant progress in their proposed merger, with the S-4 registration statement becoming effective, the HSR waiting period expiring, and shareholder votes scheduled for June 13, 2025.

Mallinckrodt reports significant progress in its planned merger with Endo, having cleared SEC and antitrust hurdles and scheduled shareholder meetings.

Mallinckrodt announces positive Q1 2025 results with top-line growth and increased Acthar sales, while progressing towards its merger with Endo expected in the second half of 2025.

Endo, Inc. announces its Q1 2025 financial results, highlighting revenue of $393 million and adjusted EBITDA of $99 million, while reaffirming its full-year financial guidance and progressing with its merger with Mallinckrodt.

Endo reaffirms its 2025 financial guidance, projecting revenues between $1,775 and $1,860 million and adjusted EBITDA between $620 and $650 million, while advancing its merger with Mallinckrodt.

Endo Pharmaceuticals reports Q1 2025 results in line with expectations, reaffirming its full-year financial guidance while progressing with the proposed merger with Mallinckrodt.

Mallinckrodt plc announced its first quarter 2025 financial results, reporting net sales of $419.9 million and reaffirming its full-year guidance, while also progressing with its planned merger with Endo, Inc.

Mallinckrodt and Endo have filed a registration statement on Form S-4 with the SEC, marking a significant step towards their planned merger expected in the second half of the year.

Endo and Mallinckrodt are progressing towards their proposed combination, having submitted necessary filings and established a transition management office, with an anticipated closing in the second half of the year.

Mallinckrodt and Endo Pharmaceuticals are merging to create a combined company with approximately $3.6 billion in revenue, aiming for a stronger balance sheet and increased investment opportunities.

Mallinckrodt and Endo Pharmaceuticals are merging to form a combined company with a stronger balance sheet and diversified portfolio, aiming to unlock growth potential and create value through a potential separation of the generics business.

Mallinckrodt and Endo have announced a definitive agreement to combine, aiming to create a global, scaled, and diversified pharmaceutical leader.

Mallinckrodt and Endo are joining forces in a merger aimed at driving concentrated growth and enhancing market position, followed by a planned spin-off of the generics and sterile injectables business.

Endo and Mallinckrodt have agreed to combine in a cash and stock transaction, aiming to establish a diversified pharmaceutical company with global scale.

Endo and Mallinckrodt plan to merge, creating a larger pharmaceutical company before spinning off the generics and sterile injectables businesses into a separate entity.

Mallinckrodt plc will acquire Endo, Inc. in a transaction aimed at combining their generics pharmaceuticals businesses and Endos sterile injectables business.

Mallinckrodt and Endo are merging to form a global pharmaceutical company with expected 2025 revenue of $3.6 billion and adjusted EBITDA of $1.2 billion, followed by a planned separation of the generics business.

Mallinckrodt and Endo have announced a merger agreement to form a diversified pharmaceutical company with global scale, alongside Endo's Q4 and full-year 2024 financial results.

Mallinckrodt and Endo have announced a definitive agreement to combine, aiming to establish a global, scaled specialty pharmaceuticals leader.

Mallinckrodt and Endo have agreed to merge, aiming to create a global, scaled, and diversified pharmaceuticals leader.

Mallinckrodt and Endo have agreed to merge, aiming to create a global, scaled, diversified pharmaceuticals leader.

Mallinckrodt and Endo have announced a definitive agreement to merge, aiming to establish a leading global pharmaceutical company, with plans to later separate the combined generics and sterile injectables business.

Mallinckrodt and Endo have announced a definitive agreement to combine, aiming to create a global, scaled, and diversified pharmaceuticals leader.

Mallinckrodt plc has filed a Rule 425 document with the SEC concerning Endo Inc., indicating ongoing communication or activity related to the company.

Mallinckrodt and Endo announce a merger agreement to create a larger, more diversified pharmaceutical company, followed by a planned separation to form a pure-play branded pharmaceuticals company.

Mallinckrodt and Endo have agreed to merge, creating a larger, more diversified pharmaceutical company with plans to later separate the combined generics business.

Mallinckrodt and Endo have entered into a definitive agreement to combine their businesses, forming a global, diversified pharmaceutical company.